These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12227234)

  • 21. Hallucinogen persisting perception disorder: what do we know after 50 years?
    Halpern JH; Pope HG
    Drug Alcohol Depend; 2003 Mar; 69(2):109-19. PubMed ID: 12609692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD.
    Halpern JH; Lerner AG; Passie T
    Curr Top Behav Neurosci; 2018; 36():333-360. PubMed ID: 27822679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing triggers to visual disturbances among individuals with positive vs negative experiences of hallucinogen-persisting perception disorder (HPPD) following LSD use.
    Lev-Ran S; Feingold D; Goodman C; Lerner AG
    Am J Addict; 2017 Sep; 26(6):568-571. PubMed ID: 28654720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EEG coherence in post-LSD visual hallucinations.
    Abraham HD; Duffy FH
    Psychiatry Res; 2001 Oct; 107(3):151-63. PubMed ID: 11566431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic Cannabis Substances (SPS) Use and Hallucinogen Persisting Perception Disorder (HPPD): Two Case Reports.
    G Lerner A; Goodman C; Bor O; Lev-Ran S
    Isr J Psychiatry Relat Sci; 2014; 51(4):277-80. PubMed ID: 25841224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hallucinogen persisting perception disorder: A literature review and three case reports.
    Skryabin VY; Vinnikova M; Nenastieva A; Alekseyuk V
    J Addict Dis; 2018; 37(3-4):268-278. PubMed ID: 31613183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review.
    Orsolini L; Papanti GD; De Berardis D; Guirguis A; Corkery JM; Schifano F
    Front Psychiatry; 2017; 8():240. PubMed ID: 29209235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hallucinogen-persisting perception disorder.
    Hermle L; Simon M; Ruchsow M; Geppert M
    Ther Adv Psychopharmacol; 2012 Oct; 2(5):199-205. PubMed ID: 23983976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stable quantitative EEG difference in post-LSD visual disorder by split-half analysis: evidence for disinhibition.
    Abraham HD; Duffy FH
    Psychiatry Res; 1996 Oct; 67(3):173-87. PubMed ID: 8912957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hallucinogenic Persisting Perception Disorder: A Case Series and Review of the Literature.
    Ford H; Fraser CL; Solly E; Clough M; Fielding J; White O; Van Der Walt A
    Front Neurol; 2022; 13():878609. PubMed ID: 35599738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LSD use and flashbacks in alcoholic patients.
    Batzer W; Ditzler T; Brown C
    J Addict Dis; 1999; 18(2):57-63. PubMed ID: 10334376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hallucinogen persisting perception disorder after ecstasy use].
    Hanck L; Schellekens AF
    Ned Tijdschr Geneeskd; 2013; 157(24):A5649. PubMed ID: 23759176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hallucinogen Persisting Perception Disorder and Risk of Suicide.
    Brodrick J; Mitchell BG
    J Pharm Pract; 2016 Aug; 29(4):431-4. PubMed ID: 25631475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment.
    Doyle MA; Ling S; Lui LMW; Fragnelli P; Teopiz KM; Ho R; Di Vincenzo JD; Rosenblat JD; Gillissie ES; Nogo D; Ceban F; Jawad MY; McIntyre RS
    Expert Opin Drug Saf; 2022 Jun; 21(6):733-743. PubMed ID: 35426769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exacerbation of hallucinogen-persisting perception disorder with risperidone.
    Morehead DB
    J Clin Psychopharmacol; 1997 Aug; 17(4):327-8. PubMed ID: 9241019
    [No Abstract]   [Full Text] [Related]  

  • 36. Improvement of hallucinogen persisting perception disorder (HPPD) with oral risperidone: case report.
    Subramanian N; Doran M
    Ir J Psychol Med; 2014 Mar; 31(1):47-49. PubMed ID: 30189471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective analysis of the "Neverending Trip" after administration of a potent full agonist of 5-HT2A receptor - 25I-NBOMe.
    Schetz D; Schetz A; Kocić I
    Biomed Pharmacother; 2022 Feb; 146():112295. PubMed ID: 34980551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases.
    Litjens RP; Brunt TM; Alderliefste GJ; Westerink RH
    Eur Neuropsychopharmacol; 2014 Aug; 24(8):1309-23. PubMed ID: 24933532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is BOL-148 hallucinogenic?
    Tfelt-Hansen P
    Cephalalgia; 2011 Apr; 31(5):634; author reply 635-6. PubMed ID: 21163816
    [No Abstract]   [Full Text] [Related]  

  • 40. Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives.
    Martinotti G; Santacroce R; Pettorruso M; Montemitro C; Spano MC; Lorusso M; di Giannantonio M; Lerner AG
    Brain Sci; 2018 Mar; 8(3):. PubMed ID: 29547576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.